|
Q4 FY2026
As of Jul 31, 2026
|
Q3 FY2026
As of Apr 30, 2026
|
Q2 FY2026
As of Jan 31, 2026
|
Q1 FY2026
As of Oct 31, 2025
|
Q4 FY2025
As of Jul 31, 2025
|
Q3 FY2025
As of Apr 30, 2025
|
Q2 FY2025
As of Jan 31, 2025
|
Q1 FY2025
As of Oct 31, 2024
|
Q4 FY2024
As of Jul 31, 2024
|
Q3 FY2024
As of Apr 30, 2024
|
Q2 FY2024
As of Jan 31, 2024
|
Q1 FY2024
As of Oct 31, 2023
|
Q4 FY2023
As of Jul 31, 2023
|
Q3 FY2023
As of Apr 30, 2023
|
Q2 FY2023
As of Jan 31, 2023
|
Q1 FY2023
As of Oct 31, 2022
|
Q4 FY2022
As of Jul 31, 2022
|
Q3 FY2022
As of Apr 30, 2022
|
Q2 FY2022
As of Jan 31, 2022
|
Q1 FY2022
As of Oct 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable, net of allowances of $2,379 and $1,166, respectively | ||||||||||||||||||||
| Unbilled accounts receivable, net | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Unbilled accounts receivable, net | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease assets | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued employee compensation | ||||||||||||||||||||
| Deferred revenue, net | ||||||||||||||||||||
| Convertible senior notes, net | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Lease liabilities | ||||||||||||||||||||
| Convertible senior notes, net | ||||||||||||||||||||
| Deferred revenue, net | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY: | ||||||||||||||||||||
| Common stock, par value $0.0001 per share—500,000,000 shares authorized as of July 31, 2026 and 2025; 81,992,467 and 84,530,418 shares issued and outstanding as of July 31, 2026 and 2025, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Retained earnings (accumulated deficit) | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
Loading...
